BioNxt Solutions appoints Terry Lynch as capital markets advisor and plans a 2025 human bioequivalence study for its multiple sclerosis sublingual Cladribine product.

BioNxt Solutions Inc., a Canadian biotech firm, has appointed Terry Lynch as its capital markets advisor. Lynch has extensive experience in biosciences and resource sectors. The company is developing a sublingual Cladribine product for multiple sclerosis, aimed at improving treatment for patients with dysphagia. Following positive animal study results, BioNxt plans a human bioequivalence study in early 2025 and is pursuing patent protections in multiple countries.